N
Google TrendSOCIAL SECURITY 2027 COLA ANNOUNCEMENT (500+) — When will 2027’s Social Security COLA be announced?
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:social security 2027 cola announcement500+benfica vs vitória sc200+energy ceasefire200+elliot anderson200+r.c.d. mallorca - u. d. las palmas200+quinyon mitchell2000+tornado north carolina1000+sean young500+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Phase 1 Data Highlight Po" (30 stories)

Top Headline Story

Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile
Lead StoryYahoo Financeworld
Sep 21

Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxOV1RUdDFSMEhaTWVjOXU0UWJLSHFCZTVMZ2RBRjNDRE0xMzMza0Z0R2ZmYnJ3ZWxDd3ZyRU1zOTBqcHlNZ0lxb2NPc3F4aEVqVTVNWUZtSVNoY1BQRlR5X0liNDFYb0ZobnpVQ2JkZUpCbFJlaVlaSjdhRUtiT2JJM2I0dXVzZDJGR0NiUzduam9wWC1w?oc=5" target="_blank">Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
500+20m ago

social security 2027 cola announcement

When will 2027’s Social Security COLA be announced?

Filter stories
200+30m ago

benfica vs vitória sc

Benfica tem 'roupa nova' para receber o V. Guimarães: o onze provável

Filter stories
200+30m ago

energy ceasefire

Trump announces partial ceasefire in Ukraine war as Zelenskyy says deal is ‘news to me’

Filter stories
200+30m ago

elliot anderson

James McAtee: How Oliver Glasner has transformed Nottingham Forest midfielder from forgotten man to his new Adam Wharton

Filter stories

Search Results for "Phase 1 Data Highlight Po"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Phase 3 NEJM Data Highlights Oveporexton's Symptom Improvement in Narcolepsy Type 1
NeurologyLivegeneral

Phase 3 NEJM Data Highlights Oveporexton's Symptom Improvement in Narcolepsy Type 1

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQYUZkTnNTVm5ycG9SV1JISk9iZ2hxUFZaUU1MRUNqNUNfdHMzWEIzTzF5TjNOM3hoQ3JWT3ljU2ZHQWo5UVhuRUVYTU9uQnk0RkJjdUtRR1RpMTJvQWNHRVVuZldWdGhpZGFZSDhDWUs4QnBKeWljM3Z1VUUzZVdzUWllc0R5WUdmTUhmamN1LTdkQjBycm5FYTY4VnEzbWhUYUxjUHB2Q0hVWHVsZ0E?oc=5" target="_blank">Phase 3 NEJM Data Highlights Oveporexton's Symptom Improvement in Narcolepsy Type 1</a>  <font color="#6f6f6f">NeurologyLive</font>

Read Full StoryMore like this
Phase 1 Data Highlight Potential Utility for In Vivo CAR T-Cell Therapy in R/R Myeloma
OncLivegeneral

Phase 1 Data Highlight Potential Utility for In Vivo CAR T-Cell Therapy in R/R Myeloma

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxOQlpFc29VMlhVMWlIaVc5eUxLTGpubkVQWTAyN1VBUzU3a2szXzJ5QlhsOFVpN3NYMmtKMG9NVldWb0dNZVBSLXMxNWNnaEdsdkxyVW5GM0x5Y2xQc3ZBdWZzM2ZJZ1ZEdnVkUWxhb1ppc1B0cnk4Ti1WNEkxczBQc0w4SnJ5LWY4U1RZdGtMa0UtMU5tczBEYmJvUlVqalJna2c0SkR2b1R5Z0VjWE5vanFXV3dvQQ?oc=5" target="_blank">Phase 1 Data Highlight Potential Utility for In Vivo CAR T-Cell Therapy in R/R Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting
PR Newswiregeneral

Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting

<a href="https://news.google.com/rss/articles/CBMipwJBVV95cUxOSlpjaURVX2xHWEllMnVITGE1eUN5aGtWVWlkMDNnckcwT1ZQOGhtTE9GZF9pWm9aYmRNeUNZVmFoaHJqMW9NcmI4d3NJS2RQSzByV3VjY3NHVzVvRzdWdFNYSUUtVEVMVzRnc09iR0FEeHh2dXpMMnNMNkVpNkdUamkxUFpvNFVsZ2tGcU9XUk40d21INGhGMmRIbGNQOU44clllRUg3bHZUeEU0VC01NGpvY0tSNFRVX0dlTjRKSG5zempyY094NkhaZDUtenZma3dycHJUemtJZmdYLXRKR0tsbkxZTE9vSVV5QWVGMVItbjlCaVNuRzB5VzlteTdxOVowM2xVTDZwYU9oNVlmYzJTUjFZYndNNVJTMkF3eHpNNjJ0ZzZZ?oc=5" target="_blank">Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile
Stock Titanworld

Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQZHR0aENUVDR4REl1YXBJb3FLYjJWOHg1LUdtMFM4UDA5UHJ4QWpjc1Z6YmpwTzF0OGdiNi1HVks5WEg5NEwzZ1BoTGo1STktN0hjbDAzczF4dE1BZlVEYTBPWDVVVHAyRERBcTZyNzZGZWp0Vm9hZUI4M0w1YWF5YW1LUVFmLS1ZWlN2R1VfNGJoT25VRzdwajdoTmJWQ2V5eTJiMk9uYzA4MVAzUlV3a2lDd0NlYkR6WGc?oc=5" target="_blank">Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile</a>  <font color="#6f6f6f">Stock Titan</font>

Read Full StoryMore like this
Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
BioSpacegeneral

Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxNeDRSb0dEblBJRkhteGpydlh5VjhiTEhFVzVZOXprMGVDNUhEcFQtMGlnUkpGSGhtcFdNOHZ2Mi1HLVhzRFE2TDc2NGtuOU5PbnFtdWUtT0VqYWZCN2IzNm1FSGN2UEVMTDlscjJZWjBiS0QzcWFhSk9ldVN4R1NqQXpiMVpFQ2UyM3pyTy1tR3lGRWhBelNaY09GcFEtdkgtZjhDRVp4Q3Uyd2pYVWZQYmNFRnhHSWFYYUVEVDBtZDZkZ0ptRjBMZW55d1FKSXdMTlBkTHZ6N2NVb1lBTU5FWjhsXzlUVkszQkd0Y0lzYlZjdw?oc=5" target="_blank">Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
Interim Trial Results and Preclinical Data Highlight Potential of ABS-201 in Androgenetic Alopecia
Dermatology Timesgeneral

Interim Trial Results and Preclinical Data Highlight Potential of ABS-201 in Androgenetic Alopecia

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxPZkxvZFJ3VGlVUVR0bXNJUE1wY01vQXM3b05xWWlVaGxsT0pVMDd2Q1NWeFB2d3ItUXlqT21QVWw0QU5RbDVBTWljNWhna19kVXNYbVMyUmdBNUhCQm45Y3VPdTR3d1ZCVGZBQUhkUFJKRmNBVHVTNkh2LUZEU25qLVN1MHBFOHl4cjRqVnV0ZGFQeGU2T3daTEZBU0x3di1GSXdza0NldjFUNnV2MjJ0RE4wYlg2ejFXZDYxSGNZU21GOERnTFhDTVo5OEs4S2FKeWc?oc=5" target="_blank">Interim Trial Results and Preclinical Data Highlight Potential of ABS-201 in Androgenetic Alopecia</a>  <font color="#6f6f6f">Dermatology Times</font>

Read Full StoryMore like this
ASCO 2026 Lung Cancer Data Highlight Advances Across Targeted Agents and Immunotherapy
Targeted Oncologyworld

ASCO 2026 Lung Cancer Data Highlight Advances Across Targeted Agents and Immunotherapy

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPR29nbVVKdmRfVl9ETUZwNFA5Tjl0RFQ4dUQ0SENyc3BEcDNwVUdsWC1WRzhva0JCNXJMQWJkRFZlUWFKbl9Kc1hlMjREaG1KNGhBMDNnSUFmaEVybk9ESU56ZVZYNFZWeG9xcXJYQlZlMzgya0dtbXp0NkNlYUpuajdOSDVxSjg1WDFqd3BuQ0FlS2R1R2xXUzRfZU45TVpJblRSQklyQVNweGZPYnBycWJSenVkY3A0aHBR?oc=5" target="_blank">ASCO 2026 Lung Cancer Data Highlight Advances Across Targeted Agents and Immunotherapy</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer
BioNTechtech

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxPWGpKR0U2YUlUd0hzcHBjQW95b3FJN3Q5YWt5b2lTN1pQYUQzVnNPa3FzRW1rYm1LU0xFTjBwNXJzanl4MkF2RndUeGZwYnVVMEZtLWQ0cFBzOHRKVDVKSk5jQVhmVGNPZ19yOEVpZEZJM0hqZWx6VUwwbGRpbVJuYzAzRkNRRWNRTjloYkRyNEZGT0VPMm1iUHk3SXR6NnRZaVg4UVZObVMtc21DR3hyZUJLMVBqTXJZVG5zMlNpZWJ1Vkg1WU9SSVZTT2g?oc=5" target="_blank">BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer</a>  <font color="#6f6f6f">BioNTech</font>

Read Full StoryMore like this
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers
Business Wireworld

Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers

<a href="https://news.google.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?oc=5" target="_blank">Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026
PR Newswiregeneral

MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026

<a href="https://news.google.com/rss/articles/CBMinwJBVV95cUxPSWdwYlpDcFNZWF8tTnJYT3B4WUxheHVOZ3UzeXJLdkItSUE3bXltQUdsTmR1RElCZEh3Qnh5aUlXTmN5akZReGxrcjg5bUpyUnFReWpyQm1nSUdKdDB6b3NEaUVOWmtvaFRUNUxQZU5FaV9ZNFpWelZUWDQ1MU9vVnh3ZFU1V2lXV0N6WVZnX0pEcTdkT3oyLVZoMHdDdGhyM2lNeGhsMVV3VnF4OGpMV3AtWE1vM3Vxb3hqb2NzcW5WeHBPZjJkSlRWbWQyaXNjdDF4YjA1SXZaWVRjbTA1dnVGN2QySWtuaW5Oa0gteDJZY2tzeDZaeldMazFtUjQwT3lZRUpYSFB2THlleXZpcV9BeWVDSHc1LXJiNnBsSQ?oc=5" target="_blank">MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Kalohexis Presents Data Highlighting Dual MC3R/MC4R Activation as a Novel Mechanism Designed to Drive Safer, Healthier and More Durable Weight Loss at ENDO 2026
BioSpacescience

Kalohexis Presents Data Highlighting Dual MC3R/MC4R Activation as a Novel Mechanism Designed to Drive Safer, Healthier and More Durable Weight Loss at ENDO 2026

<a href="https://news.google.com/rss/articles/CBMipgJBVV95cUxPdFdPM3pzRkp4NXVoM1BRMWJuNzQtZTA0SkpKRjU1b1VUdWlJcVpFMTFOZ3hOQkExSEhFODlnYXdrcGxQME5mTkF1Tl9ILVJqdUR3YzVwVHI4YWFVYmMwVDMzTVBpQV91YUJFU2lhaURoWGE2TzFMWTBSQk5RVG9LS1NnT0dmbnpib2dBS25aSURIaUVhckItdUE2cHNaOFROYmo5blRQY20wM3VoNUVkc0ozNHEwWlNhVldBbHdVVHE0WDNmbFZfSjNrbmVvMWk4ZFhtTTgwSldHblFJem1qRmRTWmRnNmhzM3AydTRJaUVBcmRSMkJ1ZlJUZjZVZHVVcTRFbFpKWWlhVWYydTYzS3VmQnN5cTZNMUpFX3NGbTdVSmpoeXc?oc=5" target="_blank">Kalohexis Presents Data Highlighting Dual MC3R/MC4R Activation as a Novel Mechanism Designed to Drive Safer, Healthier and More Durable Weight Loss at ENDO 2026</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026
GlobeNewswiregeneral

Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026

<a href="https://news.google.com/rss/articles/CBMilgJBVV95cUxPdFRaYmV0WGVTVk9TdVZEclNhanNfQjVQX19ha0t6Q2FJZFVWeDZ5UkpmdWgyY0lZNFRESW5GTjE0QmhEMk96bGFqdlFfeWFhaS0zdWozU251OHlOSEIzR1l2amg1UXpGV2Y1N1RkZE01Z1RvZkw1WlFxdV9PQ19PM2NyQ244MG82WW5NVXE1U1RwMVo2QmM2X1kwWm1oTzU3OHIzREdRdmxQdU0zSGFKS0tkb0VDbEdqRjRQV3VBZDJqa3FQdlN6Y3BpVEZWNzlDdE1OUnYteDR0V3IwLUYwM01hSXRnX1NQaEM2azhBQ09YVDVzMUZyblJTUEZxQ1dxTng5Q1BjMW9YRUZpREFxTkFySkdPUQ?oc=5" target="_blank">Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026</a>  <font color="#6f6f6f">GlobeNewswire</font>

Read Full StoryMore like this
Radiopharm Theranostics Highlights Phase 1 Pipeline, Eyes June RAD 101 Data at DB Conference
Yahoo Financeworld

Radiopharm Theranostics Highlights Phase 1 Pipeline, Eyes June RAD 101 Data at DB Conference

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxPNHRWank1U0pSR19rNUpHZ2N5eG5XRzJXeFhBVkU2dFNVVTJFX3BmejhHUWdjV0JJS2RXdXh0ZDROajhydUYyS2tYWTNoOGk1VG1BUXFGamhqcks5cTVzUmFlRGhIYzFyeVZVNVotdXRxRkxZdHFtdDJSdGpueURRQ216OUtScmhCbEFpajhiQ3VENFFpS0dtSXpHNEpRSHEzM2FKN2RyMWtORkJRUnRSUQ?oc=5" target="_blank">Radiopharm Theranostics Highlights Phase 1 Pipeline, Eyes June RAD 101 Data at DB Conference</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
Early Phase 3 Data Highlight Convenience and Feasibility of Self-Administered Alzheimer Agent Remternetug
NeurologyLivepolitics

Early Phase 3 Data Highlight Convenience and Feasibility of Self-Administered Alzheimer Agent Remternetug

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxPd3I5YWRIQkx6WXhUVUUzcl9GazR6Sl9oN2VjNl9UMVhPcERKU2lxMFdWbFR4WEdTcFBjVFNHSGZ0XzUydG1PN0h2TU5iSG1oeW84eUctNkRBdFRpN0RaY0JRYnMwc19KdEo0SGQzbFFxOVVoY0s5alduSlE3VEdPV05MMnRfQzlBZXMtN1BVUThwSkVoWGZDMzhqdGF6MHFWNDlvaUZzZWFVUVBvU0lmWXAyMTAzMlFQd25NZmtoQ2ZaRFNuMlpOLTZIV3BqQQ?oc=5" target="_blank">Early Phase 3 Data Highlight Convenience and Feasibility of Self-Administered Alzheimer Agent Remternetug</a>  <font color="#6f6f6f">NeurologyLive</font>

Read Full StoryMore like this
Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera
Business Wiregeneral

Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

<a href="https://news.google.com/rss/articles/CBMivgJBVV95cUxQWnRJR2V0Q2ZmWkJ6WHhKNlh5ZjdmQ2xhUGdGVkRZUUpkbHFrel91LXV5RkRrR1RzUExIem0tQ09zdzhZZmJJM0xfN2l3NUJOTDdCNEQ1bENYcHhSWkVSZ1BNSlJtWVJVeDdIdEFvWUpqdmFRdjlaZW9FRHd1UEFPN0IxWnB1TGVjWG9XWWNpWC0ySnBJTFJ4c3pld3FRSnVYSXRBQXkwYkNUdnhfQmlNT2RDcWN2M05aYVVvQjR2VC1KT3RST2g0Z21HWGxPbHZfckx3OXVQWUFBdGlyY3NKQmRqOGpRUUM2OW5vUGV5ZEJma3FhSl9obUVlVEZPbkdKUmZQNERKT296MWVmQ3U3MDM2WGcyNjlzRXlMTjlmQzE1RVgwcEdQNmlwbnV3MnkwVzBrOUN0dmpHN1Z6MUE?oc=5" target="_blank">Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
Immunitas Presents Phase 1/2a Data Highlighting Anti-Tumor Activity of Novel Immunotherapy IMT-009 at AACR 2026 Annual Meeting
PR Newswireworld

Immunitas Presents Phase 1/2a Data Highlighting Anti-Tumor Activity of Novel Immunotherapy IMT-009 at AACR 2026 Annual Meeting

<a href="https://news.google.com/rss/articles/CBMijgJBVV95cUxOSzItQWw3RjhLU05Da0I1dlQwY3djZy15WGk1dVlpeHJSWTYyX1VZZ2FsOVNqV3JZQVdfZUdPTXRDSFVnbEtWYzhRQUJYRF9Dbm5jMFYtR09ZVzBObDN3YnNpcE9nWk1kVUV6emEwOWN2YTNTT2pXUHdLYzBmMHNWbWM1ZUpkblhGSlpBUFNuelQ4dUNMWmpqTWVOdmZzclUtd0hzQzNZcVI0MF9NUEpiZElBekRJOVlkaVoxNjRjUUVDcDl4cU1sc0lwT0F6MjBZYzZzWHBhVVJjQ3VmZ3BLQXljRnQxcWpta3h0c1gtM0tHUS1UWkk3VXVaYzctcDllM1RtdjBrZGNOOHdVekE?oc=5" target="_blank">Immunitas Presents Phase 1/2a Data Highlighting Anti-Tumor Activity of Novel Immunotherapy IMT-009 at AACR 2026 Annual Meeting</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Positive VAX-31 Phase 1/2 Adult Data Published in The
GlobeNewswiregeneral

Positive VAX-31 Phase 1/2 Adult Data Published in The

<a href="https://news.google.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?oc=5" target="_blank">Positive VAX-31 Phase 1/2 Adult Data Published in The</a>  <font color="#6f6f6f">GlobeNewswire</font>

Read Full StoryMore like this
Zymeworks Presents New Preclinical Data at AACR 2026
GlobeNewswiregeneral

Zymeworks Presents New Preclinical Data at AACR 2026

<a href="https://news.google.com/rss/articles/CBMiuwJBVV95cUxOU21hU0R1anJ6U2xsZXg2T0JTWHdNd1FYekYzaWJFd3NhbTFmYTVTYVo4MVpydmVzMzZNRm9ZWFZUUTd5anlnOE5GaGNIY0xIV3pfMjk1eU1OMTVyMXVSWmNzc3FvZnBaSVRpeHZsNVI0aWtMUjd6ajJRT1IweEhFa0hOaVMzendVRnFoc1lSNWhpemRjaWZ0NlQydEIzb0NibmZGdWNEVGM1UU11ejRaWXRadG5kaVo3QWtidlVBN2R5aEprYTQxZkN6Z1lObXVVRm02bjhnVGFUMDdTQlEtSksyVmVnWXlCVVotcThMemFqXzBFdzFYTTZTczh5Z0FwYllsX2tlQndTcnVMb3BMRlhzbjFHbEx4Szc0eWRZTDNaNjJxWHNFNnRab3kzQnFXVkJvM1NDN0JBWG8?oc=5" target="_blank">Zymeworks Presents New Preclinical Data at AACR 2026</a>  <font color="#6f6f6f">GlobeNewswire</font>

Read Full StoryMore like this
Xencor Highlights XmAb942 Phase 1 Data, Previews TL1A/IL-23 Bispecific XmAb412 at DDW 2026
Yahoo Financegeneral

Xencor Highlights XmAb942 Phase 1 Data, Previews TL1A/IL-23 Bispecific XmAb412 at DDW 2026

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxQTlRqUzY3Q1dyNWxpX1VnZHZnaGZmWFpvUk1jVnMyc0xyNEtWZDg1TWRDV2R5c24tRmpiU1hWQmF0Wmd4alVYWDdmZG5tUEZnSDRtYUE5RXpybTBFNV9CT0RuRGNQNERtVzMtZ3BqQlEzTVFJeGVNdXVHb2EwU1ItZDY4R2trd2ZKNkRUZWx1eUpHX1RQWVdvRGNMUHlWYTRiU1IzTQ?oc=5" target="_blank">Xencor Highlights XmAb942 Phase 1 Data, Previews TL1A/IL-23 Bispecific XmAb412 at DDW 2026</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call
Investing News Networkgeneral

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxOZGN0OFVUT1M5N01ESkNEdmVsa05KWGt0UmFFZXYzMEkyZmVTWGEyVHY1aF8wQlJkbWtHdFJ4eDluM0VoSkkzQk5Ga3hoSktCNGR0TWtYaFRQYUNYRXRiLVFLdWRvdDduWnB4U2Z5dktZTjFJaW9wTjNrbE5GTS02ZG9uOEloSnhTUGZMOXN6bEEzeEZCTW0yMmFLZG5rXzNlQ2dBektsOThnQWlKVjJFb2JlVGM2MlN2TDdWX1pFX2xGOHpHQUhTZ1R5Njk?oc=5" target="_blank">AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call</a>  <font color="#6f6f6f">Investing News Network</font>

Read Full StoryMore like this
Phase 1b Asthma Data Highlight Durable IL-13 Suppression With Zumilokibart
Dermatology Timesgeneral

Phase 1b Asthma Data Highlight Durable IL-13 Suppression With Zumilokibart

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxPNk5abUZKZm9uV2g2bXN4WTQ1SzctVGV5V19LUDBUR0JteEJqbnZuZjZ1bXNBVEJlWDVMaThIaG80cGZpYXppSnBheWtFTXh6cXlWcUdyNk9oanV3c2NBRkNrMW9xT29ua3V5TnA3Szllazl6QjMzeHV2VHJRQnlLbFhOZzBSdVVtVVZKTDVxRE5POWswVHg5b0Y2bHhGUVJzM3RkU0h4c09UYkhHOTBTTXh3?oc=5" target="_blank">Phase 1b Asthma Data Highlight Durable IL-13 Suppression With Zumilokibart</a>  <font color="#6f6f6f">Dermatology Times</font>

Read Full StoryMore like this
Highlight Therapeutics illuminates positive ph. 2 topline data in high-risk skin cancer
Fierce Biotechgeneral

Highlight Therapeutics illuminates positive ph. 2 topline data in high-risk skin cancer

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNOEVUTXFFamtvQk5CTFNoZ09XTG1mX3ZHMGRBSzhncVVVU2o0azQ0cFBpSTB2aGZXalplczhHQkI1djRWNWxvdHMtbzVUaDEtSGdlYUlkZmVORWduc1NHa2djLVQwMjJTeEFhV0pJRGxpdmY0N3pWY2hrTjZmSE5TemxFLVU1Nk9wMEtBQlJzWHVhSWxta0RJSnZKaTVxbFREQjBBeVNDNy1nVHVtM1BOUHRRTFQxOEdOQzgxQUZn?oc=5" target="_blank">Highlight Therapeutics illuminates positive ph. 2 topline data in high-risk skin cancer</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
Research Rewind: Notable Phase 1/2 Breast Cancer Trial Readouts From Quarter 2 of 2026
OncLivegeneral

Research Rewind: Notable Phase 1/2 Breast Cancer Trial Readouts From Quarter 2 of 2026

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxORUhRRzBIbDRsOUI5d3lCN0lmLWFfdmdxbWdXeGlFMzhiU0x2eklFQVpYTU1mU3lQdFR0bFl5clhENUJfUzdyZU5pbE9wcWxjS19WWS1zZWliQkxiWm5vVjk4d2FmdVVUQ1AyMVluc3A3VlU5c3V4QXZtZ2RZLXhCdHUzeTdCYjFWMW0xVHEzOERHem5qcTU1RTk5cS04ak5sSWpMNGczcnNveFZiek90c1FzTE4?oc=5" target="_blank">Research Rewind: Notable Phase 1/2 Breast Cancer Trial Readouts From Quarter 2 of 2026</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Louise Emmett, MD, PhD, highlights early data on 225Ac-PSMA-617 in mCRPC
Urology Timesgeneral

Louise Emmett, MD, PhD, highlights early data on 225Ac-PSMA-617 in mCRPC

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPZm5OTzk4VmtyWUxlWDhqRzFjOTVoMVotV2FfRFc1ME5sUktpSjREVXEtLUdiVUtTQkFxUG1maS16cVRaV0IxcHQ5UHBITFJicDVWOW50UkNDSEVBY3lvRmZMV1d3VmZvOHVranVsaTN1UU9ENkppTTQ3VnBEeUJuRW9KYzZ0X0RXVkxranBURDhER3JqS0ZQODN2MmFsUQ?oc=5" target="_blank">Louise Emmett, MD, PhD, highlights early data on 225Ac-PSMA-617 in mCRPC</a>  <font color="#6f6f6f">Urology Times</font>

Read Full StoryMore like this
Phase 4 THRIVE Data Highlights Eptinezumab’s Impact on Migraine After Prior CGRP Failure
NeurologyLivetech

Phase 4 THRIVE Data Highlights Eptinezumab’s Impact on Migraine After Prior CGRP Failure

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxONkw3dmo0Y1cxSVRxX0gzNGN0amhVWHd4bmVRZ3NXTGw0cGtTMklWcVhUS243bVdDWG9TRG1NaWprRm9Md29uUzFvMDFLTDI5Q0ZsdnRXUzZ4aXBGZDlBVWFDZENIRUdZRzZickdEd01BM2JaWVpfbHNHMmRzSDY3aWI0cXhHS3dyVGRmQl81Y1pFb2I0Mkk0T0dieUtVUHdxRnAtbmF4UkJRWlA5Ym5HZFBERzAtUkdaU2c?oc=5" target="_blank">Phase 4 THRIVE Data Highlights Eptinezumab’s Impact on Migraine After Prior CGRP Failure</a>  <font color="#6f6f6f">NeurologyLive</font>

Read Full StoryMore like this
Tanya B. Dorff, MD, highlights early data on ABBV-969 in mCRPC
Urology Timesgeneral

Tanya B. Dorff, MD, highlights early data on ABBV-969 in mCRPC

<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxNSmMyZXFIcEJaN2hpRzJtNEJ6dnk3a1VHdUFEWkdraWhETW1tcnJCMC1Zc09vNXJLWW1xVF9qY0pNRkNkWTRaeXc4eVJBaFE1TjRFRmJUOFRidExoSUU5MkdJcnp0ZU9QYVBKWFY4RU1qZ1FrNmtmeWVhUDRmR0l1eHhrNUlQWE5vSE9ILXdncks?oc=5" target="_blank">Tanya B. Dorff, MD, highlights early data on ABBV-969 in mCRPC</a>  <font color="#6f6f6f">Urology Times</font>

Read Full StoryMore like this
Phase 3 Data Highlight Hair Regrowth With Deuruxolitinib in AA
AJMCtech

Phase 3 Data Highlight Hair Regrowth With Deuruxolitinib in AA

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxOR2hQVlV4X0pqSUF1R1hSN1lHaWFOb2hQZ2JOMUJNbC1SSDVNckwzLU5kcmJlb09zYVpYeTNGVzAwNHFKMGdFVl9yTHZ3WTYwb1M5c2xHM1h2UmtaNm5wZzl0YzQ1TTRScFU4c2pPOUZ3Znl2SEgzTVNWYkRabDh0SG4tWmU5YTNKNzlpeFlaNjZ5QQ?oc=5" target="_blank">Phase 3 Data Highlight Hair Regrowth With Deuruxolitinib in AA</a>  <font color="#6f6f6f">AJMC</font>

Read Full StoryMore like this
Ractigen Therapeutics Announces Landmark Publication in Nature Medicine Highlighting Unprecedented Preclinical Efficacy and Positive First-in-Human Clinical Data for RAG-17 in SOD1-ALS
PR Newswireworld

Ractigen Therapeutics Announces Landmark Publication in Nature Medicine Highlighting Unprecedented Preclinical Efficacy and Positive First-in-Human Clinical Data for RAG-17 in SOD1-ALS

<a href="https://news.google.com/rss/articles/CBMi3AJBVV95cUxPSkp6a1RJN296Q0NpcjFtTjNYUC0tclQ5ZGswMWVTQmJvTDNSSS1JM3VsdFVYNDdKMy1jS3lKUGE4ZVEtMzRnRWJTa0JOZDRaZjJYaVU3amtFQmFXTHk3Q0Q2cExOMVRiWDhvOEdQUFJSamo4M1JUT3pzb2tXaDRLQ1BxSnRFV3hURVQtNU45djdkN3dHOFJzVkgtUy03eElsN185dkFOTmdSUUhQWEhOdERDUmFsWHpyTDB4TzFWbDNjWVUzUFAxeDdNMVNvSVV2R3NVakFWTmNHRWNQNnlnMUdRLXFmRkxTY3N2TElFUGxIbnBBY1k1MGdLVGp3akVPaVFMVXNYQUxWWXRhd2xuNzNhTkNQcWMzVjRDWXFXRk42dFhVYVRZbmxPTG1sUmp5LUlaRVR1RWJhYzkwTndUdV80dFBpRkdjNmkzUGVCckJhQXlzVFBlNmlfRHY?oc=5" target="_blank">Ractigen Therapeutics Announces Landmark Publication in Nature Medicine Highlighting Unprecedented Preclinical Efficacy and Positive First-in-Human Clinical Data for RAG-17 in SOD1-ALS</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026
PR Newswiregeneral

Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026

<a href="https://news.google.com/rss/articles/CBMijwJBVV95cUxQYmFfYkxtMEVpbVJBb2JMUTBSSDl0eEJtLVpicVN3LWFodjZtRzdlb2JaS3dKNUppc2lEZDIxWldmV0VEOXg3VTIwSUx2SUE4RmlzNVczdV9zZGpZeXpxQ3NyOW83eG01Vldvb05HbmozcTFQWjZYVXhwcnNyQ2xEOUZ2cmtQWHdseHFKUlB0aFZRRFhZcFZLTjlUZmRaTlhpanZDRl9Ib181eURnTGs5S2RFWUhRbF9RWnJkVmlnamRJeUFTS1dJWVA3QVQ5YlNOQmU4TUwwVFVnWWtESHR0eGEya1VUY0FEeGpsNzhZZ2J4SlV6SU5ZdS1LOThZMDlHaDZMRzZyNGE3RDQ5d2pR?oc=5" target="_blank">Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
"Phase 1 Data Highlight Po" — Live Google News Trends & Headlines